Table 2 Treatment-related patient characteristics
Total (%) n = 275 | Age <70 years (%) n = 228 | Age ≥ 70 years (%) n = 47 | p value for group differences | |
|---|---|---|---|---|
Type of surgery | 0.019b | |||
Primary cytoreduction | 226 (82.2) | 193 (84.6) | 30 (70.2) | |
Interval debulking | 49 (17.8) | 35 (15.4) | 14 (29.8) | |
Surgical interventions | ||||
Adnectomy | 259 (94.2) | 220 (96.4) | 39 (83.0) | 0.038b |
Hysterectomy | 248 (90.2) | 212 (93.0) | 36 (76.6) | 0.006b |
Omentectomy | 255 (92.7) | 212 (93.0) | 43 (91.5) | 0.720b |
Pelvic LAE | 191 (69.5) | 171 (75.0) | 20 (42.6) | <0.001b |
Paraaortic LAE | 184 (66.9) | 166 (72.8) | 18 (38.3) | <0.001b |
Appendectomy | 110 (40.0) | 94 (41.2) | 16 (34.0) | 0.327b |
Splenectomy | 22 (8.0) | 19 (8.3) | 3 (6.4) | 1.000b |
Large bowel resection | 104 (37.8) | 87 (38.2) | 17 (36.2) | 0.798b |
Small bowel resection | 37 (13.4) | 27 (11.8) | 10 (21.3) | 0.084b |
Postop. residual tumor | 0.029b | |||
Microscopic | 189 (68.7) | 163 (71.5) | 26 (55.3) | |
Macroscopic | 86 (31.3) | 65 (28.5) | 21 (44.7) | |
Intraoperative complications | 0.532c | |||
Yes | 20 (7.2) | 16 (7.0) | 4 (8.5) | |
No | 247 (89.9) | 209 (91.7) | 38 (80.9) | |
Unknown | 8 (2.91) | 3 (1.3) | 5 (10.6) | |
Postoperative complications | 0.495b | |||
Yes | 95 (34.6) | 82 (36.0) | 13 (27.7) | |
No | 172 (62.6) | 143 (62.7) | 29 (61.7) | |
Unknown | 8 (2.9) | 3 (1.3) | 5 (10.6) | |
Mortality rates | ||||
30d-mortality rate | 0.0 % | 0.0 % | 0.0 % | 1.000d |
60d-mortality rate | 1.1 % | 0.4 % | 2.1 % | <0.001d |
Chemotherapy | ||||
courses (median, range) | 6 (1–8) | 6 (1–8) | 6 (2–6) | 0.156a |
Time to chemo after surgery (median, range) | 34 (5–188) | 34 (5–188) | 31.5 (9–127) | 0.368a |
Treatment concept | 0.019b | |||
- Neoadjuvant | 49 (17.8) | 35 (15.4) | 14 (29.8) | |
- Adjuvant | 226 (82.2) | 193 (84.6) | 30 (70.2) | |
Treatment regimen | <0.001c | |||
- Platinum-based combination | 260 (94.5) | 223 (97.8) | 37 (78.7) | |
- Platinum monotherapy | 15 (5.5) | 5 (2.2) | 10 (21.3) | |
Response to chemotherapy | 205 (74.5) | 178 (78.4) | 27 (57.4) | 0.003b |
Optimal oncologic treatment (no residual tumor + combination therapy) | <0.001b | |||
Yes | 179 (65.1) | 160 (70.1) | 19 (40.4) | |
No | 96 (34.1) | 68 (29.8) | 28 (59.6) | |
Survival (months) | ||||
Median PFS | 19 | 20 | 12 | 0.022d |
Median OS | 48 | 64 | 30 | <0.001d |